MyoKardia Inc. (MYOK) Trading Up 21%
MyoKardia Inc. (NASDAQ:MYOK)’s share price was up 21% on Tuesday . The stock traded as high as $16.35 and last traded at $16.20, with a volume of 57,920 shares. The stock had previously closed at $13.39.
Several equities analysts have commented on MYOK shares. Cowen and Company reaffirmed an “outperform” rating and issued a $24.00 price target on shares of MyoKardia in a report on Monday, March 21st. Zacks Investment Research cut MyoKardia from a “hold” rating to a “sell” rating in a report on Friday, April 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of MyoKardia in a report on Friday, March 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $21.33.
The company’s 50-day moving average is $13.18 and its 200-day moving average is $11.07. The stock’s market capitalization is $477.54 million.
MyoKardia (NASDAQ:MYOK) last posted its earnings results on Thursday, May 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.21. Equities analysts expect that MyoKardia Inc. will post ($1.56) earnings per share for the current year.
An institutional investor recently bought a new position in MyoKardia stock. Casdin Capital LLC bought a new position in MyoKardia Inc. (NASDAQ:MYOK) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 403,872 shares of the company’s stock, valued at approximately $5,921,000. MyoKardia comprises about 5.2% of Casdin Capital LLC’s portfolio, making the stock its 9th largest position. Casdin Capital LLC owned about 1.49% of MyoKardia at the end of the most recent quarter.
MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.